Interferon-alpha treats rare blood cancers by forcing mutant blood stem cells to mature rapidly into short-lived white blood cells, depleting malignant cell pools over time according to research published in Nature Genetics. Scientists at Weill Cornell Medicine used single-cell profiling to uncover the precise molecular mechanisms behind the biologic drug, explaining how it balances myeloid and lymphoid cell production in patients with myeloproliferative neoplasms like essential thrombocythemia.
Single-Cell Profiling Uncovers Cellular Shifts
Myeloproliferative neoplasms occur when genetic mutations inside blood stem cells trigger an overproduction of specific blood lineages. In essential thrombocythemia, excessive megakaryocytes drive up platelet counts, elevating patient risks for heart attacks and strokes. To map how interferon-alpha counteracts this disease process, senior author Dr. Anna Nam and her research team utilized advanced single-cell profiling tools, according to Weill Cornell Medicine. This technology allowed investigators to track gene-activity patterns and surface proteins across thousands of individual blood cells gathered from consented patients before and after treatment.
Upon examination, the data showed that interferon-alpha initiates a simulated infection defense, forcing blood stem cells to rapidly transform into short-lived white blood cells known as neutrophils. According to Dr. Anna Nam, an assistant professor of pathology and laboratory medicine at Weill Cornell Medicine and pathologist at NewYork-Presbyterian/Weill Cornell Medical Center, these discoveries offer approaches for novel methods to treat these blood cancers and potentially others as well. The research was co-led by research assistant Chhiring Lama and Dr. Danielle Isakov during her MD/PhD studies in the Nam Laboratory.
Targeting Myeloid-Lymphoid Imbalance and Inflammation
The rapid maturation into neutrophils means these cells quickly die off, which steadily depletes the pool of mutant blood stem cells. Furthermore, the single-cell data demonstrated that interferon-alpha induces many blood stem cells to produce lymphoid cells, bringing the lymphoid cell population into balance with myeloid cells. Beyond rebalancing these lineages, the therapy suppresses inflammaging-related gene programs.
While interferon-alpha remains a therapeutic option for myeloproliferative neoplasms, its broad activity frequently induces significant side effects. Investigators at Weill Cornell Medicine note that the newly mapped molecular mechanisms pave the way for more potent and selective methods to activate these processes, aiming to decrease mutant blood cells while minimizing significant side effects.
- Penn State Researcher Wins Grant for Pediatric Leukemia Treatment Study
- Does Drinking More Coffee Reduce Body Fat and Increase Muscle Mass?
- Breakthrough Salk Study Uncovers Mechanism Behind Immunotherapy Resistance: Interferons, Mitochondrial Dysfunction, and PGE2″ Interferons, mitochondrial dysfunction and PGE2: Salk study reveals mechanism behind immunotherapy resistance. Boost its search engine visibility with relevant keywords for maximum impact. Immunotherapy resistance remains one of the biggest hurdles in cancer treatment. According to a recent study published in the journal Nature Communications, scientists at the Salk Institute have made a groundbreaking discovery that sheds light on the underlying mechanisms behind this resistance. The study reveals that interferons, a type of protein that plays a crucial role in the immune system, can contribute to mitochondrial dysfunction in cancer cells. This dysfunction can lead to the production of prostaglandin E2 (PGE2), a molecule that promotes tumor growth and resistance to immunotherapy. In their study, the researchers found that PGE2 production was a key factor in the development of immunotherapy resistance in cancer cells. The team used a combination of experimental and computational models to investigate the relationship between interferons, mitochondrial dysfunction, and PGE2 production. The findings of the study suggest that targeting PGE2 production could be a potential strategy for overcoming immunotherapy resistance. The researchers propose that blocking PGE2 receptors or inhibiting its production could help restore the function of mitochondria in cancer cells, making them more susceptible to immunotherapy. The study’s authors hope that their findings will pave the way for the development of new therapies that can overcome immunotherapy resistance and improve treatment outcomes for cancer patients. Key Takeaways: – Interferons contribute to mitochondrial dysfunction in cancer cells – Mitochondrial dysfunction leads to PGE2 production, promoting tumor growth and resistance to immunotherapy – Targeting PGE2 production could be a potential strategy for overcoming immunotherapy resistance – Restoring mitochondrial function in cancer cells could make them more susceptible to immunotherapy Keywords: immunotherapy resistance, interferons, mitochondrial dysfunction, PGE2, Salk Institute, cancer treatment, breakthrough study, Nature Communications. (archyworldys.com)